A CLINICAL RESEARCH ON â??SWASAKASAMâ?? (BRONCHIAL ASTHMA) WITH SIDDHA DRUG â??THALAGA KULIGAIâ??

A PRECLINICAL AND CLINICAL STUDY ONâ??THALAGA KULIGAIâ?? FOR THE TREATMENT OF SWASAKASAM(BRONCHIAL ASTHMA)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/01/005466

Enrollment

Registered

2015-01-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- MALE AND FEMALE WITH COUGH WITH OR WITHOUT EXPECTORATION DYSPNOEA AND WHEEZE

Interventions

Intervention1: THALAGA KULIGAI: DOSAGE 1 TABLET 100MG TDS ADJUVANT HONEY DURATION 48 DAYS Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Clinical signs and symptoms of bronchial asthma Dyspnoea Wheeze Cough with or without expectoration Willing to give specimen of blood for investigation. Willing to attend the OPD once in 7 days

Exclusion criteria

Exclusion criteria: Congestive cardiac failure. Bronchiectasis. Bronchogenic carcinoma Pulmonary TB Chronic bronchitis Pregnancy Chronic bronchitis. Pregnancy

Design outcomes

Primary

Measure	Time frame
Primary outcome is mainly assessed by reduction in clinical symptoms and by comparing the peak expiratory flow rate before and after treatmentTimepoint: 48 Days	—

Secondary

Measure	Time frame
Secondary outcome is assessed by comparing the safety parameters before and after treatmentTimepoint: 48 DAYS	—

Countries

India

Contacts

Public ContactDR K KANAKAVALLI

GOVERNMENT SIDDHA MEDICAL COLLEGE

parniru@gmail.com9444284684

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026